Sequential Inc.
This article was originally published in Start Up
Executive Summary
The founders of Sequential Inc. think breast and other cancers may be the outcome of "sequential pathogenesis," the process of an abnormal macrophage causing other cells to become sick. The company has in-licensed a compound it believes will be beneficial for pre-treating breast cancer patients scheduled for surgery (a growing trend called neoadjuvant therapy). Meanwhile, Sequential is pursuing targets that may be involved in sequential pathogenesis, and developing a compound of its own.